Leniolisib Results Analyst Conference Call

Feb 3, 2022 at 8:00 AM EST

Pharming Group announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) also known as PASLI (p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency).

Watch the webcast here

Supporting Materials

Press Release 284 KB

Live Teleconference Information

Thursday February 3, 2022 14:00CET/08:00ET

Please note, the company will only take questions from dial-in attendees.

Dial in details: United Kingdom 0800 640 6441
United Kingdom (Local) 020 3936 2999
Netherlands (Local) 085 888 7233
United States 1 855 9796 654
United States (Local) 1 646 664 1960

Access code: 871929